DE68921114D1 - Oxaspiro[2,5]octan-Derivate. - Google Patents

Oxaspiro[2,5]octan-Derivate.

Info

Publication number
DE68921114D1
DE68921114D1 DE68921114T DE68921114T DE68921114D1 DE 68921114 D1 DE68921114 D1 DE 68921114D1 DE 68921114 T DE68921114 T DE 68921114T DE 68921114 T DE68921114 T DE 68921114T DE 68921114 D1 DE68921114 D1 DE 68921114D1
Authority
DE
Germany
Prior art keywords
alkylcarbamoyl
alkyl
hydroxy
alkenoyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921114T
Other languages
English (en)
Other versions
DE68921114T2 (de
Inventor
Teruo Oku
Chiyoshi Kasahara
Takehiko Ohkawa
Masashi Hashimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888819256A external-priority patent/GB8819256D0/en
Priority claimed from GB888819258A external-priority patent/GB8819258D0/en
Priority claimed from GB898908029A external-priority patent/GB8908029D0/en
Priority claimed from GB898909794A external-priority patent/GB8909794D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE68921114D1 publication Critical patent/DE68921114D1/de
Application granted granted Critical
Publication of DE68921114T2 publication Critical patent/DE68921114T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Dental Preparations (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Cereal-Derived Products (AREA)
DE68921114T 1988-08-12 1989-08-09 Oxaspiro[2,5]octan-Derivate. Expired - Fee Related DE68921114T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888819256A GB8819256D0 (en) 1988-08-12 1988-08-12 Oxaspiro(2 5)octane derivative
GB888819258A GB8819258D0 (en) 1988-08-12 1988-08-12 Oxaspiro(2 5)octane compound
GB898908029A GB8908029D0 (en) 1989-04-10 1989-04-10 Oxaspriro(2,5)octane derivative
GB898909794A GB8909794D0 (en) 1989-04-28 1989-04-28 Cyclohexane derivative

Publications (2)

Publication Number Publication Date
DE68921114D1 true DE68921114D1 (de) 1995-03-23
DE68921114T2 DE68921114T2 (de) 1995-06-08

Family

ID=27450157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921114T Expired - Fee Related DE68921114T2 (de) 1988-08-12 1989-08-09 Oxaspiro[2,5]octan-Derivate.

Country Status (18)

Country Link
US (2) US5789405A (de)
EP (1) EP0354787B1 (de)
JP (2) JP2773275B2 (de)
KR (1) KR0130765B1 (de)
CN (1) CN1051703C (de)
AT (1) ATE118490T1 (de)
AU (1) AU632056B2 (de)
CA (1) CA1340291C (de)
DE (1) DE68921114T2 (de)
DK (1) DK171987B1 (de)
ES (1) ES2067546T3 (de)
FI (1) FI97805C (de)
GR (1) GR3015382T3 (de)
HU (1) HU211569A9 (de)
IE (1) IE66923B1 (de)
IL (1) IL91250A (de)
NO (1) NO173236C (de)
PH (1) PH26256A (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
JPH0660168B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 ０―置換フマギロール誘導体
DE68927904T2 (de) * 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
JPH0660095B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 血管新生阻害剤
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP1004318A3 (de) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Zyklodextrin-zusammensetzung
CA2119233A1 (en) * 1991-09-18 1993-04-01 Fumio Shimojo Transocular pharmaceutical preparation
EP0602586B1 (de) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733499B1 (fr) * 1995-04-27 1997-05-30 Adir Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5719167A (en) * 1995-08-07 1998-02-17 Alcon Laboratories, Inc. Angiostatic compounds
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US6180626B1 (en) 1995-10-11 2001-01-30 Fujisawa Pharmaceutical Co., Ltd. Vascular-permeability suppressants
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO1999061432A1 (en) * 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AU2002239479B2 (en) * 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
KR20060130077A (ko) * 2003-12-29 2006-12-18 프래시스 파마슈티컬즈 인코포레이티드 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도
WO2007087330A2 (en) * 2006-01-24 2007-08-02 Goss International Americas, Inc. Signature hopper with lap straightening device
CA2706914A1 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CN102123586A (zh) 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
EP2435053B1 (de) 2009-05-28 2018-11-14 Mersana Therapeutics, Inc. Polyal-arzneimittelkonjugate mit in veränderlicher rate freigesetzten linkern
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
KR101696960B1 (ko) 2010-01-08 2017-01-16 자프겐 인크. 푸마길롤 타입 화합물 및 그의 제조 및 사용 방법
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2595988B1 (de) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclische verbindungen und verfahren zu ihrer herstellung
AU2011326566B2 (en) 2010-11-09 2016-12-01 Zafgen, Inc Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
KR20140009273A (ko) 2010-11-29 2014-01-22 자프겐 인크. 6-o-(4-디메틸아미노에톡시)신나모일 푸마길롤의 비-일일 투여를 사용하는 비만의 치료
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
KR101875988B1 (ko) 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
EP2705030B1 (de) 2011-05-06 2016-07-27 Zafgen, Inc. Teilweise gesättigten trizyklishen verbindungen, deren herstellung und verwendung
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
MX368966B (es) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
EP2804866B1 (de) 2012-01-18 2016-11-16 Zafgen, Inc. Tricyclische sulfonamidverbindungen sowie verfahren zur herstellung und verwendung davon
KR20140112566A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
JP6177888B2 (ja) * 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
EP3054991B1 (de) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3641826B1 (de) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Verfahren zur herstellung von wirkstofftragenden polymergerüsten und protein-polymer-wirkstoff-konjugaten
CN108530375B (zh) * 2018-05-29 2020-04-21 南京药石科技股份有限公司 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
WO2023156996A1 (en) * 2022-02-16 2023-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024040009A2 (en) * 2022-08-17 2024-02-22 Primetime Life Sciences, Llc Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
DE68927904T2 (de) * 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
JPH0660168B2 (ja) * 1988-09-01 1994-08-10 武田薬品工業株式会社 ０―置換フマギロール誘導体
DE68915900T2 (de) * 1988-09-01 1994-11-24 Takeda Chemical Industries Ltd Angiogenese hemmendes Mittel.
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.

Also Published As

Publication number Publication date
FI893794A (fi) 1990-02-13
FI97805C (fi) 1997-02-25
DK390989A (da) 1990-02-13
ATE118490T1 (de) 1995-03-15
GR3015382T3 (en) 1995-06-30
IL91250A (en) 1994-10-21
KR0130765B1 (ko) 1998-04-09
IE892505L (en) 1990-02-12
ES2067546T3 (es) 1995-04-01
HU211569A9 (en) 1995-12-28
FI893794A0 (fi) 1989-08-11
JP2773275B2 (ja) 1998-07-09
DK390989D0 (da) 1989-08-09
JP2970524B2 (ja) 1999-11-02
CN1079898A (zh) 1993-12-29
AU632056B2 (en) 1992-12-17
NO173236C (no) 1993-11-17
EP0354787B1 (de) 1995-02-15
IE66923B1 (en) 1996-02-07
FI97805B (fi) 1996-11-15
JPH08319281A (ja) 1996-12-03
JPH0285272A (ja) 1990-03-26
KR900003164A (ko) 1990-03-23
US5767293A (en) 1998-06-16
IL91250A0 (en) 1990-03-19
CA1340291C (en) 1998-12-29
DK171987B1 (da) 1997-09-08
EP0354787A1 (de) 1990-02-14
AU3945389A (en) 1990-02-15
NO893235D0 (no) 1989-08-11
CN1051703C (zh) 2000-04-26
NO173236B (no) 1993-08-09
US5789405A (en) 1998-08-04
NO893235L (no) 1990-02-13
DE68921114T2 (de) 1995-06-08
PH26256A (en) 1992-04-01

Similar Documents

Publication Publication Date Title
ATE118490T1 (de) Oxaspiro(2,5>octan-derivate.
ES2095833T3 (es) Derivados de benzodiazepinas.
RU94016183A (ru) Производные пиперазина
AU1025795A (en) Prolineamide derivatives
HU9600834D0 (en) Quinazoline derivatives
HU9300309D0 (en) Pyrazole derivatives, their production and medical preparatives containing them
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
AU693261B2 (en) Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
AU6199494A (en) New polypeptide compound and a process for preparation thereof
HUT60507A (en) Process for producing trifluoromethyl ketone derivatives and pharmaceutical compositions comprising same as active ingredient
DE68906609T2 (de) Dopamin-vorlaeufer.
RU95105435A (ru) N-замещенные производные 3-азабицикло [3.2.0]гептана в качестве нейролептического средства
FI101227B1 (fi) Menetelmä farmaseuttisesti aktiivisten 4-desoksi-4-epipodofyllotoksiinijohdannaisten valmistamiseksi
HUT51283A (en) Process for production of n-alkyl derivatives of bu-3608-antibiotics and medical compositions containing them as active substances
AU7424394A (en) 3- or 4-glycosyloxybenzopyran derivatives and antiallergic agents containing the derivatives as active ingredients
RU94045839A (ru) Производные 3-(фенилалкиламиноалкилокси)-5-фенилпиразола, а также способ и промежуточные вещества для их получения, лекарственное средство, содержащее эти соединения
NO894325D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
EP0420086A3 (en) Pyrimidoindole derivatives and processes for preparation thereof
AU7506591A (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
TH32709A (th) สารฆ่าเชื้อรา สารประกอบของมัน กรรมวิธีการผลิตสารดังกล่าว และวิธีใช้สารดังกล่าว

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee